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Human embryonic stem cells (hESCs) are hypersensitive to apoptotic stimuli, though the underlying mech-
anisms are poorly characterized. In this issue of Cell Stem Cell, Liu et al. (2013) report that mitochondria
of human ESCs exist in an apoptosis-prone state, ready to act as cellular executioners upon detecting
DNA damage.Anti- and proapoptotic factors maintain
the proper balance between protecting
cells from premature elimination and pro-
tecting the organism when individual cells
go haywire. Exogenous stresses, which
can cause DNA double-strand breaks
and loss of genome integrity, challenge
this balance and force a life-or-death
decision. Human embryonic stem cells
(hESCs) are exceptionally sensitive to
DNA damage, compared to differentiated
cells, and quickly undergo apoptosis in
response to stress rather than attempting
repair of a compromised genome. The
mechanisms behind this apoptosis-prone
state, and the role of the tumor suppres-
sor p53 in this process, are not well
understood.
In this issue of Cell Stem Cell, Liu
and colleagues (2013) demonstrate that
this susceptibility of hESCs to undergo
apoptosis is due to a high state of
‘‘mitochondrial priming’’: a lowered cell-
intrinsic threshold for initiating apoptosis,
based on the balance of pro- and antia-
poptotic proteins. Antiapoptotic factors,
such as BCL-XL, protect the mitochondria
from permeabilisation, allowing the cell
to repair the DNA damage. In contrast,
proapoptotic factors, such as Bak or
Bax, generate pores in the mitochondrial
membrane, which is an irreversible step
in the termination of the runaway cell
(Youle and Strasser, 2008). The balance
between these two responses determines
the intrinsic apoptotic threshold. The tu-
mor suppressor protein p53 is an impor-
tant mediator of the cell’s response to
DNA damage (Vogelstein et al., 2000;
Vousden and Lane, 2007); DNA damageinduces p53 and activates the transcrip-
tion of proapoptotic genes. In the cyto-
plasm, p53 associates with mitochondrial
proteins and triggers apoptosis, either by
sequestering antiapoptotic proteins or
activating the oligomerization of pro-
apoptotic proteins, Bax and Bak (Green
and Kroemer, 2009). The relationship
between p53, mitochondrial priming, and
hESC sensitivity was thus far not clear.
To investigate the mechanisms under-
lying the increased sensitivity of hESCs
to DNA damage, Liu et al. (2013) first
explored the role of p53 in the apoptotic
response to neocarzinostatin (NCS)-
induced DNA double-strand breaks
(DSBs). They observed that siRNA knock-
down of p53 eliminated the apoptotic
response that, in line with findings of
other laboratories (Grandela et al., 2007;
Qin et al., 2007), confirms the essential
role of p53 in DNA damage-induced
apoptosis. Furthermore, inhibition of
Mdm2, a negative regulator of p53,
resulted in p53 stabilization and elicited
an apoptotic response in hESCs. One
potential mechanism explaining the
heightened sensitivity of hESCs to DNA
damage is differential expression of
p53 downstream target genes in hESCs
compared to differentiated cells. Unex-
pectedly, Liu et al. (2013) did not observe
a difference in the p53 transcriptional
response. A potent inhibitor of tran-
scription, a-amanitin, did not affect
the p53-dependent apoptotic response,
suggesting that the inductionofp53down-
stream target genes is not the primary
mechanism of DSB-induced apoptosis
in hESCs. Instead, an exclusively cyto-Cell Stem Cell 1plasmic mutant of p53 could rescue the
apoptosis defect in p53 knockdown
hESCs, demonstrating that the cyto-
plasmic form of p53 is an important medi-
ator of DNA damage-induced apoptosis in
these cells. While these findings clearly
define a role for p53 in controlling
apoptosis in hESCs, they do not explain
the heightened sensitivity of hESCs
compared to differentiated cells.
Liu et al. (2013) therefore explored
whether alternative, hESC-intrinsic pro-
perties could explain their heightened
sensitivity to DNA damage. Liu et al.
(2013) used aBH3profiling assay to deter-
mine levels of mitochondrial priming. This
assaymeasuresmitochondrialmembrane
permeabilisation (MOMP) upon exposure
to BH3 peptides from proapoptotic pro-
teins and can therefore gauge the intrinsic
balance of pro- and antiapoptotic proteins
acting on the mitochondrial membrane.
Liu et al. (2013) demonstrate that hESCs
have a much stronger MOMP response
following the addition of BH3 peptides of
proapoptotic proteins than did differenti-
ated cells. Remarkably, the heightened
hESCmitochondrial primingwas indepen-
dent of p53, as it was also observed when
p53was silenced. Instead, Liu et al. (2013)
observed that undifferentiated cells ex-
press lower levels of the antiapoptotic
protein Bcl-2 and higher levels of the pro-
apoptotic protein PUMA. Thus, it appears
that the balance is shifted toward the
proapoptotic end of the spectrum in
hESCs, which may be responsible for
their apoptosis-primed state.
To test this last hypothesis, Liu et al.
(2013) asked whether inhibiting the3, October 3, 2013 ª2013 Elsevier Inc. 371
Figure 1. Lower Apoptotic Threshold in Human Embryonic Stem Cells Compared to Differentiated Cells
The apoptotic threshold of cells is determined by the balance between pro- and antiapoptotic factors. In this issue ofCell Stem Cell, Liu et al. (2013) demonstrate
that human ESCs display high ‘‘mitochondrial priming,’’ skewing this balance in favor of proapoptotic factors and lowering the apoptotic threshold. Their findings
explain the high sensitivity of human ESCs to DNA damage.
(A) Human ESCs express higher levels of proapoptotic factors, such as Bax, Bad, and PUMA (red) and lower levels of antiapoptotic factors such as Bcl-2 (green).
This is further supported by Dumitru et al. (2012), who demonstrated that the proapoptotic factor Bax exists in a preactivated state in human ESCs but is retained
at the Golgi to prevent premature apoptosis.
(B) Differentiated cells express higher levels of antiapoptotic factors (green) and lower levels of proapoptotic factors (red), which are not in a preactivated state,
making these cells less prone to apoptosis upon DNA damage.
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ated cells would lower the apoptotic
threshold to levels observed in hESCs.
Indeed, upon inhibition of Bcl-2 with
ABT-263, a BH3-mimetic drug (Tse et al.,
2008), differentiated cells became more
sensitive to DSB-induced apoptosis.
Furthermore, while differentiated cells
were insensitive to the ectopic expres-
sion of cytoplasmic p53, they rapidly un-
derwent apoptosis in the presence of
ABT-263.
The findings of Liu et al. (2013) raise
new questions. How is the differential
expression of pro-and antiapoptotic
proteins regulated in hESCs, and how
is it resolved upon differentiation? Are
there additional players involved? How
is cytoplasmic p53 activity coupled
to mitochondrial priming in hESCs? A
recent report from Dumitru and col-
leagues (Dumitru et al., 2012) provides
further insight into this question, demon-
strating that the proapoptotic protein
Bax exists in a preactivated state in
hESCs but not in differentiated cells. To
prevent precocious apoptosis of hESCs,
this preactivated Bax is sequestered at
the Golgi. DNA damage results in rapid
translocation of preactivated Bax to the
mitochondria, and this translocation is
p53 dependent.
Thus, hESCs appear to be continuously
teetering on the brink of apoptotic cell372 Cell Stem Cell 13, October 3, 2013 ª201death. By skewing the balance between
pro-and antiapoptotic components to-
ward proapoptotic proteins, which may
exist in a preactivated state, hESCs lower
their apoptotic threshold (Figure 1) and
undergo apoptosis upon p53 induction.
In contrast, differentiated cells have a
higher threshold and, as a result, p53
does not induce apoptosis in these cells
in response to the same stimuli. These
unexpected findings provide new insight
into how apoptotic networks participate
in maintaining a high level of genomic
integrity in hESCs, despite the high
proliferative pressure that characterizes
these cells. By lowering the tolerance for
error, the emergence and propagation
of mutations is strictly prevented. It will
be interesting to explore whether similar
protective mechanisms function in resi-
dent stem cell populations of rapidly
proliferating tissues as well, such as the
intestinal and skin epithelium and pro-
genitors in the hematopoietic system. In
addition, a recent study has shown that
the level of mitochondrial priming in
85 tested tumors strongly correlated
with clinical response to chemotherapy
(Ni Chonghaile et al., 2011), suggesting
that these protective mechanisms are
activated even in genetically abnormal
cells. Therefore, better understanding
the regulatory mechanisms that maintain
this lowered apoptotic threshold may3 Elsevier Inc.provide novel insights in the pathogenesis
of and/or therapeutic approaches for
cancers as well.REFERENCES
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